CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M.
Minson A, et al. Among authors: xie j.
Blood. 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306.
Blood. 2024.
PMID: 37883795
Clinical Trial.